NCT01452750

Brief Summary

The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD), compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of non-steroidal anti-Inflammatory drug (NSAID).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
642

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Oct 2011

Geographic Reach
1 country

102 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 16, 2011

Completed
15 days until next milestone

Study Start

First participant enrolled

October 1, 2011

Completed
16 days until next milestone

First Posted

Study publicly available on registry

October 17, 2011

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

February 5, 2014

Status Verified

February 1, 2014

Enrollment Period

1.7 years

First QC Date

September 16, 2011

Last Update Submit

February 4, 2014

Conditions

Keywords

Drug Therapy

Outcome Measures

Primary Outcomes (1)

  • Recurrence rate of gastric or duodenal ulcer within 24 weeks

    Mucosal defects with a white coating of 3 mm or larger will be determined as ulcers. Recurrence rate of gastric or duodenal ulcer within 24 weeks will be calculated for each treatment group.

    24 weeks

Secondary Outcomes (5)

  • Recurrence rate of gastric or duodenal ulcer within 12 weeks

    12 weeks

  • Gastric mucosal injury

    24 Weeks

  • Duodenal mucosal injury

    24 weeks

  • Occurrence rate of hemorrhagic lesion in stomach or duodenum

    24 weeks

  • Time to recurrence of gastric or duodenal ulcer

    24 weeks

Study Arms (3)

TAK-438 10 mg QD

EXPERIMENTAL
Drug: TAK-438Drug: Placebo

TAK-438 20 mg QD

EXPERIMENTAL
Drug: TAK-438Drug: Placebo

Lansoprazole 15 mg QD

ACTIVE COMPARATOR
Drug: LansoprazoleDrug: Placebo

Interventions

TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.

TAK-438 10 mg QD

Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.

TAK-438 10 mg QD

Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.

Also known as: AG-1749
Lansoprazole 15 mg QD

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants who require continuous NSAID therapy during the treatment period with the study drug
  • Participants who have a history of ulcer in stomach or duodenum, endoscopically confirmed
  • Outpatient (including inpatient for examinations)

You may not qualify if:

  • Participants scheduled to change the type and dosage regimen of NSAID
  • Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed
  • Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology
  • Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery
  • Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
  • Participants with a previous or current history of aspirin-induced asthma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (102)

Unknown Facility

Kasugai-shi, Aichi-ken, Japan

Location

Unknown Facility

Nagoya, Aichi-ken, Japan

Location

Unknown Facility

Seto-shi, Aichi-ken, Japan

Location

Unknown Facility

Akita, Akita, Japan

Location

Unknown Facility

Funabashi-shi, Chiba, Japan

Location

Unknown Facility

Ichihara-shi, Chiba, Japan

Location

Unknown Facility

Nagareyama-shi, Chiba, Japan

Location

Unknown Facility

Matsuyama, Ehime, Japan

Location

Unknown Facility

Niihama-shi, Ehime, Japan

Location

Unknown Facility

Saijo-shi, Ehime, Japan

Location

Unknown Facility

Fukui-shi, Fukui, Japan

Location

Unknown Facility

Fukuoka, Fukuoka, Japan

Location

Unknown Facility

Itoshima-shi, Fukuoka, Japan

Location

Unknown Facility

Kitakyusyu-shi, Fukuoka, Japan

Location

Unknown Facility

Munakata-shi, Fukuoka, Japan

Location

Unknown Facility

Onga-gun, Fukuoka, Japan

Location

Unknown Facility

Tagawa-shi, Fukuoka, Japan

Location

Unknown Facility

Yukuhashi-shi, Fukuoka, Japan

Location

Unknown Facility

Fukushima, Fukushima, Japan

Location

Unknown Facility

Koriyama-shi, Fukushima, Japan

Location

Unknown Facility

Gifu, Gifu, Japan

Location

Unknown Facility

Mebashi-shi, Gunma, Japan

Location

Unknown Facility

Takasaki-shi, Gunma, Japan

Location

Unknown Facility

Fukuyama-shi, Hiroshima, Japan

Location

Unknown Facility

Hatsukaichi-shi, Hiroshima, Japan

Location

Unknown Facility

Higashihirosima-shi, Hiroshima, Japan

Location

Unknown Facility

Asahikawa-shi, Hokkaido, Japan

Location

Unknown Facility

Hakodate-shi, Hokkaido, Japan

Location

Unknown Facility

Obihiro-shi, Hokkaido, Japan

Location

Unknown Facility

Sapporo, Hokkaido, Japan

Location

Unknown Facility

Sunagawa-shi, Hokkaido, Japan

Location

Unknown Facility

Tomakomai-shi, Hokkaido, Japan

Location

Unknown Facility

Akashi-shi, Hyōgo, Japan

Location

Unknown Facility

Himeji-shi, Hyōgo, Japan

Location

Unknown Facility

Itami-shi, Hyōgo, Japan

Location

Unknown Facility

Kako-gun, Hyōgo, Japan

Location

Unknown Facility

Kato-shi, Hyōgo, Japan

Location

Unknown Facility

Kobe, Hyōgo, Japan

Location

Unknown Facility

Nishinomiya-shi, Hyōgo, Japan

Location

Unknown Facility

Higashiibaragi-gun, Ibaragi, Japan

Location

Unknown Facility

Koga-shi, Ibaragi, Japan

Location

Unknown Facility

Mito, Ibaragi, Japan

Location

Unknown Facility

Hitachi-shi, Ibaraki, Japan

Location

Unknown Facility

Hakusan-shi, Ishikawa-ken, Japan

Location

Unknown Facility

Komatsu-shi, Ishikawa-ken, Japan

Location

Unknown Facility

Takamatsu, Kagawa-ken, Japan

Location

Unknown Facility

Kamakura-shi, Kanagawa, Japan

Location

Unknown Facility

Kawasaki-shi, Kanagawa, Japan

Location

Unknown Facility

Sagamihara-shi, Kanagawa, Japan

Location

Unknown Facility

Yokohama, Kanagawa, Japan

Location

Unknown Facility

Kochi, Kochi, Japan

Location

Unknown Facility

Kumamoto, Kumamoto, Japan

Location

Unknown Facility

Uji-shi, Kyoto, Japan

Location

Unknown Facility

Tsu, Mie-ken, Japan

Location

Unknown Facility

Sendai, Miyagi, Japan

Location

Unknown Facility

Matsumoto-shi, Nagano, Japan

Location

Unknown Facility

Nagano, Nagano, Japan

Location

Unknown Facility

Nagasaki, Nagasaki, Japan

Location

Unknown Facility

Ikoma-shi, Nara, Japan

Location

Unknown Facility

Nara, Nara, Japan

Location

Unknown Facility

Nigata-shi, Niigata, Japan

Location

Unknown Facility

Beppu-shi, Oita Prefecture, Japan

Location

Unknown Facility

Ōita, Oita Prefecture, Japan

Location

Unknown Facility

Yuhu-shi, Oita Prefecture, Japan

Location

Unknown Facility

Kurashiki-shi, Okayama-ken, Japan

Location

Unknown Facility

Higashiosaka-shi, Osaka, Japan

Location

Unknown Facility

Moriguchi-shi, Osaka, Japan

Location

Unknown Facility

Osaka, Osaka, Japan

Location

Unknown Facility

Osakasayama-shi, Osaka, Japan

Location

Unknown Facility

Tondabayashi-shi, Osaka, Japan

Location

Unknown Facility

Ogi-shi, Saga-ken, Japan

Location

Unknown Facility

Saga, Saga-ken, Japan

Location

Unknown Facility

Ageo-shi, Saitama, Japan

Location

Unknown Facility

Hiki-gun, Saitama, Japan

Location

Unknown Facility

Kasukabe-shi, Saitama, Japan

Location

Unknown Facility

Kumagaya-shi, Saitama, Japan

Location

Unknown Facility

Saitama-shi, Saitama, Japan

Location

Unknown Facility

Sayama-shi, Saitama, Japan

Location

Unknown Facility

Toda-shi, Saitama, Japan

Location

Unknown Facility

Tokorozawa-shi, Saitama, Japan

Location

Unknown Facility

Ōtsu, Shiga, Japan

Location

Unknown Facility

Izumo-shi, Shimane, Japan

Location

Unknown Facility

Hamamatsu, Shizuoka, Japan

Location

Unknown Facility

Shizuoka, Shizuoka, Japan

Location

Unknown Facility

Naruto-shi, Tokushima, Japan

Location

Unknown Facility

Adachi-ku, Tokyo, Japan

Location

Unknown Facility

Bunkyo-ku, Tokyo, Japan

Location

Unknown Facility

Hachiouji-shi, Tokyo, Japan

Location

Unknown Facility

Koto-ku, Tokyo, Japan

Location

Unknown Facility

Meguro-ku, Tokyo, Japan

Location

Unknown Facility

Minato-ku, Tokyo, Japan

Location

Unknown Facility

Mitaka-shi, Tokyo, Japan

Location

Unknown Facility

Musashimurayama-shi, Tokyo, Japan

Location

Unknown Facility

Nakano-ku, Tokyo, Japan

Location

Unknown Facility

Ōta-ku, Tokyo, Japan

Location

Unknown Facility

Setagaya-ku, Tokyo, Japan

Location

Unknown Facility

Sumida-ku, Tokyo, Japan

Location

Unknown Facility

Yonago-shi, Tottori, Japan

Location

Unknown Facility

Tonami-shi, Toyama, Japan

Location

Unknown Facility

Toyama, Toyama, Japan

Location

Unknown Facility

Shimonoseki-shi, Yamaguchi, Japan

Location

Unknown Facility

Ube-shi, Yamaguchi, Japan

Location

Related Publications (1)

  • Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, Ashida K, Sugano K. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018 Jun;67(6):1042-1051. doi: 10.1136/gutjnl-2017-314010. Epub 2017 Oct 7.

MeSH Terms

Conditions

Stomach UlcerDuodenal Ulcer

Interventions

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineLansoprazole

Condition Hierarchy (Ancestors)

Peptic UlcerDuodenal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesStomach Diseases

Intervention Hierarchy (Ancestors)

2-PyridinylmethylsulfinylbenzimidazolesSulfoxidesSulfur CompoundsOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Senior Manager

    Takeda

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 16, 2011

First Posted

October 17, 2011

Study Start

October 1, 2011

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

February 5, 2014

Record last verified: 2014-02

Locations